Scilex Holding (SCLXW) Intangibles (2021 - 2026)
Scilex Holding (SCLXW) recorded quarterly Intangibles of $59.8 million in Q1 2026, down 34.84% quarter-over-quarter from $91.8 million in Q4 2025, and down 1.6% on a YoY basis from $60.8 million in Q1 2025.
Scilex Holding (SCLXW) Intangibles (2021 - 2026) Analysis & Trends
Scilex Holding's Intangibles history runs 6 years deep, the most recent figure standing at $59.8 million for Q1 2026.
- In Q1 2026, Intangibles fell 1.6% year-over-year to $59.8 million; the TTM figure through Mar 2026 stood at $59.8 million (down 1.6% YoY), while the FY2025 annual figure was $91.8 million, up 51.0% from the prior year.
- Intangibles was $59.8 million for Q1 2026 at Scilex Holding, down from $91.8 million in the prior quarter.
- In the past five years, Intangibles ranged from a high of $91.8 million in Q4 2025 to a low of $5.0 million in Q1 2022.
- Historically, Intangibles has averaged $42.2 million across 5 years, with a median of $38.5 million in 2023.
- The sharpest annual moves came in 2023 and 2025: Intangibles surged 1115.62% in 2023, then sank 48.27% in 2025.
- A 5-year view of Intangibles shows it stood at $40.6 million in 2022, then soared by 49.74% to $60.8 million in 2023, then changed by 0.0% to $60.8 million in 2024, then surged by 51.0% to $91.8 million in 2025, then sank by 34.84% to $59.8 million in 2026.
- The last three Intangibles figures came in at $59.8 million (Q1 2026), $91.8 million (Q4 2025), and $30.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | 24.45 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 7.37 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 49.06 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 50.87 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 25.75 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 21.38 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 16.38 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 52.56 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 18.24 Bn |
| 10 | Scilex Holding | - | - | 4.15 Mn | 59.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 59.81 Mn |
| Dec 31, 2025 | 91.78 Mn |
| Sep 30, 2025 | 30.42 Mn |
| Jun 30, 2025 | 31.44 Mn |
| Mar 31, 2025 | 60.78 Mn |
| Dec 31, 2024 | 60.78 Mn |
| Sep 30, 2024 | 33.45 Mn |
| Jun 30, 2024 | 60.78 Mn |
| Mar 31, 2024 | 35.46 Mn |
| Dec 31, 2023 | 60.78 Mn |
| Sep 30, 2023 | 37.51 Mn |
| Jun 30, 2023 | 38.54 Mn |
| Mar 31, 2023 | 60.78 Mn |
| Dec 31, 2022 | 40.59 Mn |
| Sep 30, 2022 | 5.00 Mn |
| Jun 30, 2022 | 5.00 Mn |
| Mar 31, 2022 | 5.00 Mn |
| Dec 31, 2021 | 38.80 Mn |